Comparison between 18F-FDG and Alternative Tracers for the Assessment of Hematological Ma-Lignancies

A special issue of Hematology Reports (ISSN 2038-8330).

Deadline for manuscript submissions: 27 June 2024 | Viewed by 1230

Special Issue Editors


E-Mail Website
Guest Editor
Nuclear Medicine Department of Asst Spedali Civili Di Brescia, Università Degli Studi Di Brescia, 25123 Brescia, Italy
Interests: PET/CT; oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
Nuclear Medicine, ASST Spedali Civili di Brescia, Università degli Studi di Brescia, Brescia, Italy
Interests: magnetic resonance; computed tomography; diagnostic radiology; ultrasonography; musculoskeletal sonography; musculoskeletal imaging; imaging; diffusion magnetic resonance imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

nuclear medicine evolves really fast and new positron emitters tracers are available year after year. Starting from preclinical evaluation, these radiopharmaceuticals are then used for clinical assessment in a high variety of diagnostic fields, including neoplasms, inflammatory or infectious diseases. Positron emission tomography/computed tomography (PET/CT) is moreover becoming pivotal for the assessment of many disorders and hematology is one of the main field of application of such diagnostic procedure. In this setting, lymphomas and related conditions are normally assessed with 18F-fluorodeoxyglucose (18F-FDG) PET/CT that is also able to give fundamental prognostic data, guiding the choice of the correct therapy. Many tracers are starting however to be used for the evaluation of hematological malignancies and for this Special Issue, I would like to invite authors to submit studies focusing on the use of these new tracers for the assessment of such disorders. Authors are welcome to cover other specific topics that have not been mentioned but fall within the theme of the Special Issue.

Dr. Francesco Dondi
Dr. Domenico Albano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT
  • 18F-FDG
  • lymphoma
  • FAPI
  • pentixafor positron emission tomography

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

10 pages, 256 KiB  
Review
Emerging Role of [18F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results
by Anna Giulia Nappi, Giulia Santo, Lorenzo Jonghi-Lavarini, Alberto Miceli, Achille Lazzarato, Flavia La Torre, Francesco Dondi and Joana Gorica
Hematol. Rep. 2024, 16(1), 32-41; https://doi.org/10.3390/hematolrep16010004 - 11 Jan 2024
Cited by 1 | Viewed by 873
Abstract
Fluorine-18 fluorodeoxyglucose ([18F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors [...] Read more.
Fluorine-18 fluorodeoxyglucose ([18F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors that are infiltrated by macrophages and other inflammatory cells. In this context, 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) has been shown to be a promising imaging biomarker of hematological malignant cell proliferation. In this review, a total of 15 papers were reviewed to collect literature data regarding the clinical application of [18F]FLT PET/CT in hematological malignancies. This imaging modality seems to be a suitable tool for noninvasive assessment of tumor grading, also showing a correlation with Ki-67 immunostaining. Moreover, [18F]FLT PET/CT demonstrated high sensitivity in detecting aggressive lymphoma lesions, especially when applying a standardized uptake value (SUV) cutoff of 3. At baseline, the potential of [18F]FLT imaging as a predictive tool is demonstrated by the low tracer uptake in patients with a complete response. However, its use is limited in evaluating bone diseases due to its high physiological uptake in bone marrow. Interim [18F]FLT PET/CT (iFLT) has the potential to identify high-risk patients with greater precision than [18F]FDG PET/CT, optimizing risk-adapted therapy strategies. Moreover, [18F]FLT uptake showed a greater ability to differentiate tumor from inflammation compared to [18F]FDG, allowing the reduction of false-positive findings and making the first one a more selective tracer. Finally, FLT emerges as a superior independent predictor of PFS and OS compared to FDG and ensures a reliable early response assessment with greater accuracy and predictive value. Full article
Back to TopTop